홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /화합물

3-(1-Methylpyrrolidin-2-yl)pyridine

HCID 942
새 노트새 반응견적 요청하기
인쇄 미리보기
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
22083-74-5
표준 SMILES
CN1CCCC1c1cccnc1
InChIKey
SNICXCGAKADSCV-UHFFFAOYSA-N
분자식
C10H14N2
평균 분자량
162.23 g/mol
단동위원소 질량
162.11569846

개요

3-(1-methylpyrrolidin-2-yl)pyridine is an N-alkylpyrrolidine that consists of N-methylpyrrolidine bearing a pyridin-3-yl substituent at position 2. It is a pyridine alkaloid, a pyrrolidine alkaloid and a N-alkylpyrrolidine.

이름 및 식별자

우선 이름
3-(1-Methylpyrrolidin-2-yl)pyridine
IUPAC
3-(1-methylpyrrolidin-2-yl)pyridine

이름 및 동의어

3-(1-methylpyrrolidin-2-yl)pyridineDL-NicotineDTXSID3048154CHEBI:1380003-[1-Methylpyrrolidin-2-yl]pyridineRefChem:489602(+-)NICOTINEDTXCID9028128623-834-222083-74-5(+/-)-Nicotine(R,S)-Nicotine
이름 더 보기
rac-Nicotine(RS)-Nicotine(+-)-Nicotine75202-10-7CHEMBL440464S-(-)-Nicotinedestruxolfumeto bac

데이터베이스 식별자

CAS
22083-74-5、54-11-5
PubChem CID
942
DTXSID
DTXSID3048154
ChEMBL
CHEMBL440464
ChEBI
CHEBI:138000
EC Number
623-834-2
Nikkaji
J23.948H

물성

구조 계산 물성

XLogP
1.2
극성 표면적
16.1 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
2
회전 가능 결합 수
1
무거운 원자 수
12
형식 전하
0
복잡도
147

실험 및 물리화학적 성질

DrugsPharmaceuticals

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (92.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P262, P264, P270, P273, P280, P301+P316, P302+P352, P316, P321, P330, P361+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 3 (92.7%)

독성 정보

Treatment · 1건

Other supportive measures include diazepam or barbiturates for seizures, atropine for excessive bronchial secretions or diarrhea, respiratory support for respiratory failure, and vigorous fluid support for hypotension and cardiovascular collapse. (L1712)

Health EffectsNicotine has mood-altering effects that may include relaxation, sharpness, calmness, and alertness. It may act as a stimulant or sedative/pain killer, depending on the dosage. (L327)
Exposure Routes · 1건

Oral (L327) ; Inhalation (L327) Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.

Toxicity Summary · 1건

Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed up of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allows more calcium to enter the axon terminal. Calcium stimulates vesicle trafficking towards the plasma membrane and the release of dopamine into the synapse. Dopamine binding to its receptors is responsible the euphoric and addictive properties of nicotine. Nicotine also binds to nicotinic acetylcholine receptors on the chromaffin cells in the adrenal medulla. Binding opens the ion channel allowing influx of sodium, causing depolarization of the cell, which activates voltage-gated calcium channels. Calcium triggers the release of epinephrine from intracellular vesicles into the bloodstream, which causes vasoconstriction, increased blood pressure, increased heart rate, and increased blood sugar.

화학 및 산업

약리 정보

Metabolism/Metabolites · 2건

Nicotine has known human metabolites that include Nicotine N-glucuronide.

As nicotine enters the body, it is distributed quickly through the bloodstream and can cross the blood-brain barrier. On average it takes about seven seconds for the substance to reach the brain when inhaled. The half life of nicotine in the body is around two hours. Nicotine is metabolized in the liver by cytochrome P450 enzymes (mostly CYP2A6, and also by CYP2B6). A major metabolite is cotinine. Other primary metabolites include nicotine N'-oxide, nornicotine, nicotine isomethonium ion, 2-hydroxynicotine and nicotine glucuronide. (L327) Route of Elimination: About 10% of the nicotine absorbed is excreted unchanged in the urine. Half Life: Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours

용도 및 제조

Uses · 1건

Nicotine is highly toxic alkaloid found in the nightshade family of plants (Solanaceae). (L327) NICOTROL Inhaler is indicated as an aid to smoking cessation for the relief of nicotine withdrawal symptoms. NICOTROL Inhaler therapy is recommended for use as part of a comprehensive behavioral smoking cessation program. It is used for the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.

관련 반응

61건
반응 기록 만들기
HRID 11750 반응식
HRID 11750반응물로uspto-grants-2006_08
HRID 15380 반응식
HRID 15380반응물로uspto-grants-2010_06
HRID 31084 반응식
HRID 31084반응물로uspto-grants-2008_09
HRID 44666 반응식
HRID 44666반응물로uspto-grants-2013_09
HRID 55545 반응식
HRID 55545반응물로uspto-grants-1997_04
HRID 59711 반응식
HRID 59711생성물로uspto-grants-2016_09
HRID 175040 반응식
HRID 175040생성물로Training data from https://doi.org/10.1039/C8SC04228D (6/10)
HRID 218056 반응식
HRID 218056반응물로uspto-grants-2012_06
1 / 8 페이지

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
더보기
새 노트새 반응견적 요청하기
Signs and SymptomsSymptoms of overdose include nausea, abdominal pain, vomiting, diarrhea, diaphoresis, flushing, dizziness, disturbed hearing and vision, confusion, weakness, palpitations, altered respiration and hypotension.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataLD50: 140 mg/kg (Dermal, Rat) LD50: 25 mg/kg (Subcutaneous, Rat) LD50: 5900 ug/kg (Intraperitoneal, Mouse) LD50: 2.8 mg/kg (Intravenous, Rat) (T80) LD50: 24 mg/kg (Oral, Mouse) (T18)